0001764013-24-000046.txt : 20240404 0001764013-24-000046.hdr.sgml : 20240404 20240404162712 ACCESSION NUMBER: 0001764013-24-000046 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240402 FILED AS OF DATE: 20240404 DATE AS OF CHANGE: 20240404 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Barnett Eva Renee CENTRAL INDEX KEY: 0001883766 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38906 FILM NUMBER: 24823461 MAIL ADDRESS: STREET 1: C/O IMMUNOVANT, INC. STREET 2: 320 WEST 37TH STREET, 6TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10018 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Immunovant, Inc. CENTRAL INDEX KEY: 0001764013 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 832771572 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 320 WEST 37TH STREET CITY: NEW YORK STATE: NY ZIP: 10018 BUSINESS PHONE: 917-580-3099 MAIL ADDRESS: STREET 1: 320 WEST 37TH STREET CITY: NEW YORK STATE: NY ZIP: 10018 FORMER COMPANY: FORMER CONFORMED NAME: Health Sciences Acquisitions Corp DATE OF NAME CHANGE: 20190108 4 1 wk-form4_1712262419.xml FORM 4 X0508 4 2024-04-02 0 0001764013 Immunovant, Inc. IMVT 0001883766 Barnett Eva Renee C/O IMMUNOVANT, INC. 320 W 37TH STREET, 6TH FLOOR NEW YORK NY 10018 0 1 0 0 Chief Financial Officer 0 Common Stock 2024-04-02 4 A 0 54978 0 A 375398 D Stock Option (right to buy) 30.78 2024-04-02 4 A 0 68723 0 A 2034-04-02 Common Stock 68723 68723 D These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on April 2, 2025, and the remainder will vest in substantially equal installments on a quarterly basis over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. The shares underlying the options will vest as to 25% of the shares on April 2, 2025 and the remainder will vest in 36 substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. /s/ Eva Renee Barnett 2024-04-04